ShockCO-OP Consortium - Shock and acute Conditions OutcOmes Platform

Scientific coordinators

Shir Lynn Lim (National University Heart Centre, Singapore)

Alastair Proudfoot (Barts Heart Centre, Barts Health NHS Trust, London, UK)

Sabri Soussi (Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada)

Steering committee

Susanna Price (Royal Brompton Hospital, Imperial College London, London, UK)

Patrick Lawler (McGill University Health Centre, McGill University, Montreal, QC, Canada)

Filio Billia (Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada)

Naoki Sato (Kawaguchi Cardiovascular and Respiratory Hospital, Kawaguchi, Japan)

Alexandre Mebazaa (Lariboisière - Saint-Louis Hospitals, Assistance Publique-Hôpitaux de Paris Nord, University of Paris Cité, France)

About the ShockCO-OP consortium

The Shock and Acute Conditions Outcomes Platform (ShockCO-OP) is a global consortium focused on advancing translational research with a focus on precision medicine approaches in the management of cardiogenic shock (CS).  

It is an open, inclusive platform, welcoming participation from any interested investigators to build a ‘Network of Networks’ in translational CS research. ShockCO-OP aims to address key challenges in the field of CS by fostering longitudinal, paired clinical and biological data sharing. The goal of the ShockCO-OP is to accelerate biological/molecular sub-phenotyping in CS to enhance precision medicine approaches and overcome sample size limitations that have hindered progress in the field.

Further, ShockCO-OP endeavors to serve as a forum for thought leaders and research networks to interface and collaborate with standardization of protocols including prospective biospecimen collection, biomarker measurement, and the use of machine learning approaches to maximize efficiency and quality.

The core aims of ShockCO-OP are:

  • To foster and champion a global collaboration amongst established CS research networks.

  • To support the development of local capacity for investigator-led research through mentorship, specifically in underrepresented regions.

  • To advance the science and methodology of translational research in CS with a focus on biological/molecular subphenotyping and precision medicine approaches.

  • To explore secondary hypotheses and disentangle the heterogeneity observed within CS populations and their clinical outcomes

  • To explore biological/molecular subphenotypes in cardiogenic shock that may be targeted in mechanistic trials and support prognostic/predictive trial enrichment.

Requesting Collaboration Through the ShockCO-OP Consortium Portal 

The ShockCO-OP portal team can help connect you with potential collaborators (i.e., translational researchers, trialists, biostatisticians, industry scientists) across the Network of Networks. Whether you're seeking study sites for funded research, partners to co-design a project using ShockCO-OP resources, or individuals with specialized expertise, we can support your outreach. 

Here is how the process works: 

  • The ShockCO-OP portal team hosts an informational webinar to share your request with the Network of Networks. 

  • Each Network partner receives the information and distributes it internally. 

  • The ShockCO-OP portal team gathers questions and contact details from interested parties and provides them to you. 

While the ShockCO-OP portal can offer guidance on site scope of work and budget expectations, the requestor is typically responsible for executing study-specific agreements directly with participating sites. 

References

Mebazaa A, Soussi S. Precision Medicine in Cardiogenic Shock: We Are Almost There! JACC Heart Fail. 2023;11(10):1316-1319. 

Soussi S, Tarvasmäki T, Kimmoun A, Ahmadiankalati M, Azibani F, Dos Santos CC, Duarte K, Gayat E, Jentzer JC, Harjola VP, Hibbert B, Jung C, Johan L, Levy B, Lu Z, Lawler PR, Marshall JC, Pöss J, Sadoune M, Nguyen A, Raynor A, Peoc'h K, Thiele H, Mathew R, Mebazaa A. Identifying biomarker-driven subphenotypes of cardiogenic shock: analysis of prospective cohorts and randomized controlled trials. EClinicalMedicine. 2024;79:103013. 

Soussi S, Price S, Proudfoot A, Mebazaa A, Lawler PR. Why Molecular Subphenotyping Is Needed in Cardiogenic Shock, and How to Accomplish This? Am J Respir Crit Care Med. 2025 Jan 13 [Epub ahead of print]. 

Contact

If you are interested in more information or would like to join the ShockCO-OP consortium, please contact ShockCO-OP@uhn.ca